Healthcare Triangle, Inc. (HCTI) · Oct 27, 2026 · Other events
Nasdaq compliance action — 1-for-20 split; shares reduced from ~17.73M to ~886,501
Healthcare Triangle’s reverse split is now effective, shrinking shares 20-to-1 as the company works to regain Nasdaq’s $1 minimum bid compliance.
Healthcare Triangle is trying to shift from a small healthcare IT provider toward a broader AI-enabled platform, including customer-engagement and healthcare technology operations; its latest quarterly filing showed sharply higher revenue but continued losses and limited cash, making access to public-market financing and listing status strategically important.
This filing executes a previously telegraphed listing-defense measure, not a business milestone. The company completed the 1-for-20 reverse split effective October 26, reducing shares from approximately 17.73 million to approximately 886,501. 〔0〕 The stated purpose is to lift the quoted share price above Nasdaq’s $1 minimum bid requirement.
The important context is that this is another attempt after a recent split, underscoring a persistent listing problem. Healthcare Triangle completed a 1-for-60 reverse split in February 2026, and Nasdaq had said the company was not eligible for its normal compliance period because of prior reverse splits. That makes the 1-for-20 action more urgent than routine share arithmetic, but it still does not demonstrate improved operations or guarantee that compliance has been regained.
The capital structure changes, while the underlying business does not. The filing leaves authorized shares and par value unchanged, so this is primarily a mechanical consolidation rather than new funding, debt reduction, or a change in strategy.
Bottom line: This confirms a known Nasdaq-compliance maneuver and keeps the listing issue alive; it does not materially advance Healthcare Triangle’s operating or AI-growth story by itself.
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!